Abstract:Accumulating evidence indicates that intratumoral heterogeneity contributes to the development of resistance to anticancer therapeutics. Fibroblasts, which are components of the paraneoplastic stroma, play a crucial role in the wound-healing process. Activated fibroblasts accumulate in the wound and are involved in many aspects of the tissue remodeling cascade that initiates the repair process and prevents further tissue damage. The pathophysiological roles of cancer-associated fibroblasts (CAFs) in the heterogeneous tumor microenvironment have attracted increasing interest. CAFs play crucial roles in tumor progression and the response to chemotherapy. Several cytokines and chemokines are involved in the conversion of normal fibroblasts into CAFs, and some of these form a feedback loop between cancer cells and CAFs. In addition, the physical force between tumor cells and CAFs promotes cooperative invasion or co-migration of both types of cells. Pro-inflammatory cytokines, such as leukemia inhibitory factor (LIF) and interleukin-6 (IL-6), are secreted by both cancer cells and CAFs, and mediate the epigenetic modification of CAFs. This enhances the pro-tumorigenic function of CAFs mediated by promoting actomyosin contractility and extracellular matrix remodeling to form the tracks used for collective cancer cell migration. The concept of intra-tumoral CAF heterogeneity refers to the presence of inflammatory CAFs with low levels of α-smooth muscle actin (α-SMA) and high levels of IL-6 expression, which are in striking contrast to transforming growth factor-β (TGF-β)-dependent myofibroblastic CAFs with high α-SMA expression levels. CAF populations that suppress tumor growth and progression through stroma-specific Hedgehog (Hh) activation have been detected in different murine tumor models including those of the bladder, colon, and pancreas. A new therapeutic strategy targeting CAFs is the "stromal switch," in which tumor-promoting CAFs are changed into tumor-retarding CAFs with attenuated stromal stiffness. Several molecular mechanisms that can be exploited to design personalized anticancer therapies targeting CAFs remain to be elucidated. Strategies aimed at targeting the tumor stroma as well as tumor cells themselves have attracted academic attention for their application in precision medicine. This novel review discusses the role of the activation of EGFR, Wnt/β-catenin, Hippo, TGF-β, and JAK/STAT cascades in CAFs in relation to the chemoresistance and invasive/metastatic behavior of cancer cells. For instance, although activated EGFR signaling contributes to collective cell migration in cooperation with CAFs, an activated Hippo pathway is responsible for stromal stiffness resulting in the collapse of neoplastic blood vessels. Therefore, identifying the signaling pathways that are activated under specific conditions is crucial for precision medicine.

Identification of Small-Molecule Inhibitors Targeting Different Signaling Pathways in Cancer-Associated Fibroblast Reprogramming Under Tumor-Stroma Interaction

Cancer-Associated Fibroblasts Suppress Cancer Development: The Other Side of the Coin

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets

Cancer-associated fibroblasts: from basic science to anticancer therapy

Abstract LB321: Identification of a novel mode of action and scaffold for modulation of cancer-associated fibroblast through Chip-seq analysis

Biomarkers for cancer-associated fibroblasts

Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities

Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives

Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance

Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer

Cancer Associated Fibroblasts: an Essential Role in the Tumor Microenvironment

Therapeutic Targeting of Cancer-Associated Fibroblasts in the Non-Small Cell Lung Cancer Tumor Microenvironment

Cancer associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy

Reprogramming of Cancer-Associated Fibroblasts Combined with Immune Checkpoint Inhibitors: A Potential Therapeutic Strategy for Cancers.

Unmasking carcinoma-associated fibroblasts: Key transformation player within the tumor microenvironment

Identification and characterization of FGFR2+ hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma

Identification of cancer-associated fibroblasts subtypes in prostate cancer

Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy